Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.61 |
| ▸ | PPARD | Q03181 | 11/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.57 |
| ▸ | PPARG | P37231 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | FABP2 | P12104 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6638762 | 0.90 | ADRB3 (0.59) | PPARAPPARDADRB3PPARGALDH1A1 | |
| SCHEMBL4576063 | 0.89 | PPARA (0.50) | PPARAPPARDADRB3PPARGALDH1A1 | |
| SCHEMBL6407513 | 0.88 | KDM4E (0.64) | PPARAPPARDADRB3PPARGALDH1A1 | |
| SCHEMBL4575333 | 0.87 | PPARA (0.48) | PPARAPPARDADRB3PPARGALDH1A1 | |
| SCHEMBL4575310 | 0.86 | PPARA (0.50) | PPARAPPARDADRB3PPARGALDH1A1 | |
| SCHEMBL5436500 | 0.83 | PPARA (0.60) | PPARAPPARDPPARG | |
| SCHEMBL3371243 | 0.81 | PPARA (0.64) | PPARAPPARDPPARGALDH1A1FABP2 | |
| SCHEMBL4575114 | 0.81 | PPARA (0.58) | PPARAPPARDPPARG | |
| SCHEMBL3848024 | 0.80 | ADRB3 (0.73) | PPARAPPARDADRB3PPARGALDH1A1 | |
| SCHEMBL4615722 | 0.79 | MAPK14 (0.74) | PPARAPPARDPPARGALDH1A1FABP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1480957-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-1449835-A2 | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003074495-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | PPARA 2/4885PPARD 3/4885ADRB3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.